Strategies to overcome statin intolerance

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 6, 2015, Pages 851-855

  Agouridis, Aris P ^a,b   Nair, Devaki R ^b   Mikhailidis, Dimitri P ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Combination therapy; Ezetimibe; Low density lipoprotein cholesterol targets; Myopathy; Statin intolerance

Indexed keywords

ANACETRAPIB; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NUTRACEUTICAL; PHYTOSTEROL; UBIDECARENONE; HYPOCHOLESTEROLEMIC AGENT;

APHERESIS; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; HUMAN; MYOPATHY; REVIEW; BLOOD; DOSE RESPONSE; DRUG DESIGN;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84929930185     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.1027685     Document Type: Review

References (41)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-934
2. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
3. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014;168:6-15
4. Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014;8(3 Suppl):S58-71
5. Guyton JR, Bays HE, Grundy SM, et al. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 2014;8(3 Suppl):S72-81
6. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-4
7. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Management of statin-intolerant high-risk patients. Curr Vasc Pharmacol 2010;8:632-7
8. Neal RC, Ferdinand KC, Ycas J, Miller E. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med 2009;122:73-8
9. Krasuski RA, Doeppenschmidt D, Henry JS, et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. Mayo Clin Proc 2005;80:1163-8
10. Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipidlowering therapies. Clin Ther 2006;28:933-42
11. Kennedy SP, Barnas GP, Schmidt MJ, et al. Efficacy and tolerability of onceweekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol 2011;5:308-15
12. Backes JM, Gibson CA, Ruisinger JF, et al. The high-dose rosuvastatin once weekly study (the HD-ROWS). J Clin Lipidol 2012;6:362-7
13. Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008;42:341-6
14. Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008;101:483-5
15. Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008;101:1747-8
16. Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002;144:674-7
17. Meek C, Wierzbicki AS, Jewkes C, et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin 2012;28:371-8
18. Kohno T. Report of the American Heart Association (AHA) Scientific Sessions 2014, Chicago. Circ J 2014;79(1):34-40
19. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183-92
20. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011;27:1191-210
21. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2, 722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009;265:568-80
22. Venero CV, Venero JV, Seip RL, Thompson PD. Effectiveness of thrice weekly ezetimibe. Am J Cardiol 2008;102:1205-6
23. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009;15:490-516
24. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review. Diabet Med 2014;31:2-14
25. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs 2008;17:1599-614
26. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8
27. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrate-associated adverse effects beyond muscle and liver toxicity. Curr Pharm Des 2008;14:574-87
28. Kalil RS, Wang JH, de Boer IH, et al. Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney Int 2015. [Epub ahead of print]
29. Derdemezis CS, Filippatos TD, Mikhailidis DP, Elisaf MS. Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering. J Cardiovasc Pharmacol Ther 2010;15:120-34
30. Chen G, Wang H, Zhang X, Yang ST. Nutraceuticals and functional foods in the management of hyperlipidemia. Crit Rev Food Sci Nutr 2014;54:1180-201
31. Agouridis AP, Filippatos TD, Tsimihodimos V, Elisaf MS. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther 2011;9:355-66
32. Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des 2010;16:3401-16
33. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
34. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97:1198-205
35. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462-8
36. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statininduced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015;90:24-34
37. Lui M, Garberich R, Strauss C, et al. Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia. J Lipids 2014;2014:864317
38. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin 2008;24:3059-62
39. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia- A systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2015;178:111-6
40. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014;24:4-15
41. Florentin M, Kostapanos MS, Kei A, Elisaf MS. Emerging drugs for hyperlipidaemia: an update. Expert Opin Emerg Drugs 2014;19:471-88